Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Optimus Holding completes acquisition of OM Pharma, strengthening biotech cluster in Switzerland

· Full commitment of Optimus Holding and its shareholders to the sustainable growth of OM Pharma · More than CHF 250 million investment in R&D and other projects planned · Expansion of manufacturing capacities in Meyrin/Geneva already decidedMeyrin/Geneva, Switzerland, 30 September 2020 – Today, Optimus Holding announced the successful closing of the acquisition of OM Pharma, a global biotech company headquartered in Meyrin, Geneva. The new owners, led by Etienne Jornod, are committed to invest more than CHF 250 million over the next few years in the development of microbial-derived

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)

Lund, Sweden, 12:00 CET, 30 September 2020 – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone injuries, today announced a change in the number of shares and votes. During September, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased with 138,925 due to the exercise of warrants. As of 30 September 2020, the number of shares in BONESUPPORT HOLDING AB (publ) amounts to 64,958,097 shares, of which 63,723,097 are ordinary shares with one vote per share and 1,235,000 are series C shares with one-tenth of a vote per share.

Change of number of shares and votes in Readly

The number of shares and votes in Readly International AB (publ) (“Readly” or the “Company”) has changed as a result of the share issue carried out in connection with the listing on Nasdaq Stockholm on 17 September 2020.Through the share issue, the number of outstanding shares and votes in the Company has increased by 7,672,118, from 29,114,330 to 36,741,448. The Company's registered share capital has increased by SEK 228,813.54, from SEK 873,429.90 to SEK 1,102,243.44. For more information, please contact: Contact for investors and analysts: Annika Billberg, Head of Investor

Wärtsilä appoints Håkan Agnevall as next President and CEO

Wärtsilä Corporation, stock exchange release, 30 September 2020 at 13:00 EESTWärtsilä appoints Håkan Agnevall as next President and CEOWärtsilä’s Board of Directors has appointed Håkan Agnevall, born 1966, M.Sc. (Tech), MBA, as the new President and CEO for Wärtsilä Corporation. Mr Agnevall will commence in his role no later than in April 2021. He will succeed Jaakko Eskola, who will continue as a senior advisor to the Board and executive team until he retires on June 30, 2021. Håkan Agnevall is currently President of Volvo Bus Corporation within Volvo Group, a position he has held

Welcome to ES Energy Save

Today is the first day of trading in ES Energy Save Holding, which is the seventh company to become listed on Spotlight Stock Market this year.ES Energy Save is a technology company focused on the energy sector. The company specializes in the development of heat pump technology. The technology is based on the proprietary platform and is delivered both as complete solutions and as plug-ins for temporary installations. Prior to the listing on Spotlight Stock Market, shares were offered to the public. The offering was subscribed for a total of approximately 119,1 million SEK, corresponding

Adapteo Plc: Managers' Transactions - Sophia Mattsson-Linnala

Adapteo Plc Managers’ transactions 30 September 2020 at 11:30 a.m. CEST ____________________________________________ Person subject to the notification requirementName: Mattsson-Linnala, SophiaPosition: Member of the Board/Deputy memberIssuer: Adapteo PlcLEI: 549300PDEX0KMLMDNZ32 Notification type: INITIAL NOTIFICATIONReference number: 549300PDEX0KMLMDNZ32_202009292912147_8____________________________________________ Transaction date: 2020-09-29Venue: NASDAQ STOCKHOLM AB (XSTO)Instrument type: SHAREISIN: FI4000383898Nature of the transaction: ACQUISITION

Australian customers select C-RAD’s cutting edge SIGRT solution

C-RAD announced today that multiple sites in the state of New South Wales, Australia decided to implement C-RAD’s Catalyst+ HD™ and Sentinel 4DCT™ solution. In total four sites in the state of New South Wales of are going to be equipped with the C-RAD solution over the next months. The Catalyst+ HD™ system is delivered with the complete software suite with modules for Respiratory Gating, Patient Setup and Positioning and Motion Monitoring. The C-RAD SIGRT solution provides a continuous monitoring of the patient during a treatment fraction. Patient motion above a clinically defined

Conversion of shares in Skanska AB

In conjunction with a conversion of shares, the company is obliged, according to the Financial Instruments Trading Act (1991:980), to disclose information concerning the change.During September 2020, 600 Series A shares were converted to Series B shares at the request of shareholders. Accordingly, the total number of votes in the company totals 597,064,148. The total number of registered shares in the company amounts to 419,903,072, of which 19,684,564 are Series A shares, and 400,218,508 are Series B shares.

Konecranes to deliver over 40 lifting products to Wärtsilä's Smart Technology Hub in Vaasa, Finland

Konecranes has won an order to deliver over 40 next-generation lifting products to the Smart Technology Hub, a new integrated center of research, product development and production in Vaskiluoto, Vaasa owned by Wärtsilä Finland, with a preliminary agreement for additional lifting products. The order was booked in September 2020.”Wärtsilä is moving closer to turning our visions of a Smart Marine Ecosystem and a 100% renewable energy future into reality by designing and establishing the Smart Technology Hub. It is a technology, innovation and validation centre with leading manufacturing and

Neandertal gene variant increases risk of severe COVID-19

A study published in Nature shows that a segment of DNA that causes their carriers to have an up to three times higher risk of developing severe COVID-19 is inherited from Neandertals. The study was conducted by researchers at Karolinska Institutet and Max Planck Institute for Evolutionary Anthropology.COVID-19 affects some people much more severely than others. Some reasons for this – such as old age – are already known, but other as yet unknown factors also play a role. This summer, a large international study linked a gene cluster on chromosome 3 to a higher risk of hospitalisation and

Kamux’s Shareholders’ Nomination Board Has Been Appointed

Kamux Corporation    Stock Exchange Release    30 September 2020 at 12:00 Kamux’s Shareholders’ Nomination Board Has Been Appointed Kamux’s Shareholders’ Nomination Board has been established according to the resolution of the Annual General Meeting held on April 21, 2020. The purpose of the Shareholders’ Nomination Board is to annually prepare and present to the Annual General Meeting, and to Extraordinary General Meeting when necessary, the proposals for the composition of the Board of Directors (the amount of members and the persons) and for the renumeration in accordance with the

Vestas wins 184 MW order in USA and secures 10 GW of order intake in 2020

News release from Vestas-American Wind TechnologyPortland, 30 September 2020 Vestas has received a 184 MW order of V120-2.2 MW and V110-2.2 MW wind turbines in the USA, which takes Vestas’ order intake in 2020 across the 10 GW mark before entering the fourth quarter.The order includes supply and commissioning of the turbines as well as a multi-year service agreement. Turbine delivery is scheduled to begin the second quarter of 2021, with commissioning scheduled for the fourth quarter of 2021. The customer and project are undisclosed per the customer’s request.For more

TR-1: S tandard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS[][][][][][][]NOTIFICATION OFMAJOR HOLDINGS(tobe sent to therelevant issuerandto the FCA inMicrosoft Wordformatif possible)[i] 1a. Identity of Faron Pharmaceuticalsthe issuer or the Ltdunderlying issuerof existingsharesto which votingrights areattached[ii]:1b. Pleaseindicate if theissuer isa non-UK issuer (please markwithan “X” ifappropriate)Non-UK issuer X2. Reason for thenotification(

Invitation to Ascelia Pharma’s virtual Capital Markets Day

Ascelia Pharma AB (publ) (ticker: ACE) hereby invites analysts, investors and media to its virtual Capital Markets Day on Wednesday October 21, 2020. Focus of the day will be on Mangoral market opportunity and preparations for commercialization.Live Q&A webcastThe virtual event consists of presentations from Ascelia Pharma executives followed by a live Q&A webcast. The presentations will be available on Ascelia Pharma’s website www.ascelia.com on October 21 at 08:00 a.m. CET. The livestreamed Q&A webcast with will take place on October 21 from 14:00-15:00 CET. A recording of the Q&A

New number of shares and votes in Nolato AB (publ)

The incentive programme for senior executives that was introduced at the extraordinary general meeting of 5 December 2016 entitles holders of Series 2 share warrants to subscribe for new shares in the company between 1 May and 15 December 2020. In September a total of 153,000 Class B shares were subscribed for through the exercise of share warrants received from the incentive programme. Prior to the issue of the new shares there were 26,581,308 shares and 51,415,908 votes in the company. At 30 September 2020 there are a total of 26,734,308 shares and 51,568,908 votes in the company. These

Vestas receives 185 MW order in the USA

News release from Vestas-American Wind TechnologyPortland, 30 September 2020 Vestas has received a 185 MW order of V150-4.2 MW turbines in 4.3 MW Power Optimised Mode for a wind project in the USA.  The order includes supply and commissioning of the turbines as well as a 20-year service agreement, designed to ensure optimised performance for the lifetime of the project. Turbine delivery is scheduled for the second quarter of 2021 with commissioning scheduled for the fourth quarter of 2021. “We’re pleased to expand the V150 footprint in the U.S.”, said Austin Schroll, Senior Director

Nordic Nanovector ASA - Tranche 1 share capital increase registered

Oslo, Norway, 30 September 2020 Reference is made to the stock exchange announcement on 23 September 2020 regarding the successful completion of Nordic Nanovector ASA's (OSE: NANO) (the "Company") private placement of new shares (the "Private Placement"). The Private Placement is divided into two tranches, as further explained in the stock exchange announcement on 23 September 2020. The share capital increase pertaining to the 6,850,350 new shares, each with a nominal value of NOK 0.20, to be issued in tranche 1 of the Private Placement (the "Tranche 1 Shares") has been registered in

Offer document regarding GB HoldCo AB's cash offer to the shareholders in Gunnebo Aktiebolag made public

­This press release is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to legislation and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled "Important information" at the end of this press

Report from the Extraordinary General Meeting in Wallenstam AB

Today, on September 30, 2020, an Extraordinary General Meeting was held in Wallenstam AB (publ). The Extraordinary General Meeting resolved, in accordance with the Board of Director’s proposal, to pay a dividend for the 2019 financial year of SEK 0.50 per share. The record day for the payment was set as October 2, 2020 and disbursement from Euroclear Sweden AB is expected to take place on October 7, 2020.

Full patient enrolment in Phase IIa Menstrual Migraine study

Asarina Pharma AB (publ) (ASAP: FN Stockholm) has reached full patient enrolment in its Phase IIa menstrual migraine (MM) study. 158 women have been recruited as scheduled at seven test centers across Sweden and Finland despite Covid-19 restrictions. Sepranolone, the endogenous compound being tested for MM, is the first therapy to focus exclusively on menstrual migraine. MM affects 50 million women worldwide and is resistant to standard migraine treatments including the new CGRP antibodies. Topline results are expected in Q2 2021.In the Spring of 2020, four of Asarina Pharma’s seven test

AFRY to design a chlorine dioxide plant for Metsä Fibre's bioproduct mill

Metsä Fibre Oy, part of the Metsä Group, and AFRY have entered into a preliminary agreement for the engineering, project management and site services of the chlorine dioxide plant at the Kemi bioproduct mill in Finland. The project is a continuation of AFRY's previous basic design of the chlorine dioxide plant.The chlorine dioxide plant will be implemented by using the EPCM project model, in which the Canadian based company ERCO is responsible for process technology solutions and supply of the main process equipment. The salt fraction generated in the production of chlorine dioxide will be

Metsä Fibre signed a preliminary agreement with ERCO and AFRY on the chlorine dioxide plant of the Kemi bioproduct mill

Metsä Fibre press release 30.9.2020Metsä Fibre, part of Metsä Group, and ERCO Worldwide have signed a preliminary agreement on the delivery of process technology and main equipment for the chlorine dioxide plant of the Kemi bioproduct mill. The process technology will be based on ERCO’s latest R8/R10 technology, which is in use, for example, at the chlorine dioxide plant of Metsä Fibre’s pulp mill in Joutseno. The salt fraction generated in the production of chlorine dioxide will be used in the closed chemical cycle of the bioproduct mill, contributing to our high material efficiency.

Number of shares and votes in Calliditas Therapeutics

During September, Calliditas Therapeutics AB (publ) has allotted 111,250 common shares within the company’s warrant program issued in 2017. Thus, as of September 30, 2020, the number of shares and votes in the company amounts to 49,941,584. For further information, please contact: Mikael Widell, Investor relations Tel.: +46 703 11 99 60, email: mikael.widell@calliditas.com The information in the press release is such that Calliditas Therapeutics AB (publ) is required to disclose pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for

Establishment of Nomination Committee in I.A.R. Systems Group AB

Stockholm, Sweden—September 30, 2020— In accordance with the Annual General Meeting April 29, 2020, the Nomination Committee is composed to include Jonas Eixmann appointed by Andra AP-fonden, Ossian Ekdahl appointed by Första AP-fonden and Evert Carlsson appointed by Swedbank Robur Fonder. Jonas Eixmann was appointed Chairman.The task of the nominating committee is to propose the Chairman at the annual general meeting 2021, Chairman and other members of the board as well as suggesting remuneration and other compensation for each of the board members. The Nominating Committee shall also

There are no items matching the current filter
There are no more items matching the current filter
Back to top